IP Library Granted Patent US 9,789,221
Granted Patent B2
US 9,789,221 · App. 14/178,086 · Granted Oct 17, 2017

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,789,221
App. No.
14/178,086
Granted
Oct 17, 2017
Kind
B2
Abstract

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (17)

1. A method of producing a phase invertible composition, said method comprising:

combining:

(a) a liquid proteinaceous substrate; and

(b) a liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and a glycosaminoglycan, wherein the liquid crosslinking composition has been formed prior to combining with the liquid proteinaceous substrate to produce said phase invertible composition;

wherein said phase invertible composition is exposed to radiation.

2. The method according to claim 1 , wherein the radiation sterilizes the phase invertible composition.

3. The method according to claim 1 , wherein the radiation is gamma radiation.

4. The method according to claim 1 , wherein the radiation is electron beam radiation.

5. The method according to claim 1 , wherein said glycosaminoglycan is hyaluronan.

6. The method according to claim 1 , wherein said proteinaceous substrate comprises a proteinaceous material selected from the group consisting of: albumin, elastin, fibrin and soluble and insoluble forms of collagen and combinations thereof.

7. The method according to claim 6 , wherein said liquid aldehyde crosslinking agent comprises glutaraldehyde.

8. The method according to claim 7 , wherein said glutaraldehyde is heat stabilized.

9. A method of producing a phase invertible composition, said method comprising:

combining:

(a) a liquid proteinaceous substrate; and

(b) a liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and hyaluronic acid, wherein the liquid crosslinking composition has been formed prior to combining with the liquid proteinaceous substrate to produce said phase invertible composition;

wherein said phase invertible composition is exposed to radiation.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2016
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 039519/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2014
From: DIECK, RONALD; HANDLEY, IAN J.; WINTERBOTTOM, NEIL; WONG, JOANNA
To: TENAXIS MEDICAL, INC.
Reel/Frame 032202/0823 →